Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…
- Sanford Bismarck Medical Center — Bismarck, North Dakota
- Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
- Essentia Health - Jamestown Clinic — Jamestown, North Dakota